Clinical experience with metiamide.
The new histamine H2-receptor antagonist, metiamide, was shown to inhibit acid and pepsin secretion in gastric secretion studies performed on patients suffering from peptic ulceration. The new drug was administered intravenously in these experiments, but effective plasma levels could also be produced by oral administration. When symptomatic patients were treated with the drug nearly all experienced marked symptomatic relief, and there was some evidence that ulcer healing occurred during treatment. When the drug was withdrawn symptoms tended to return. No toxic reactions were encountered in this trial. Double-blind studies are now being made in Britain to establish the place metiamide may have in the treatment of duodenal ulceration.
D003864:Depression, Chemical; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D006801:Humans; D008297:Male; D008785:Metiamide / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D013890:Thiourea / Q000031:analogs & derivatives*
D008785:Metiamide; D013890:Thiourea